Today GlycoMimetics, Inc. (GLYC) Stock Reaches All-Time High

February 15, 2018 - By Linda Rogers

Investors sentiment decreased to 1.08 in 2017 Q3. Its down 0.83, from 1.91 in 2017Q2. It dropped, as 13 investors sold GlycoMimetics, Inc. shares while 11 reduced holdings. 5 funds opened positions while 21 raised stakes. 28.80 million shares or 2.36% less from 29.49 million shares in 2017Q2 were reported.
Artal invested in 0.05% or 202,500 shares. Columbus Circle Investors invested in 201,980 shares. Royal Retail Bank Of Canada invested in 0% or 9 shares. The North Carolina-based First Personal Svcs has invested 0.01% in GlycoMimetics, Inc. (NASDAQ:GLYC). Prentiss Smith Co Inc holds 0.08% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC) for 10,000 shares. Parametric Port Assocs Limited Com accumulated 77,056 shares or 0% of the stock. Blackrock reported 524,610 shares. Comml Bank Of America De holds 0% or 125 shares. Vanguard Group has invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Jennison Associates Limited Liability Com reported 1.59 million shares. Td Asset Inc accumulated 25,300 shares. Nea Mngmt Lc stated it has 4.21% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC). Moreover, Natl Bank Of Mellon Corp has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 93,769 shares. Price T Rowe Associates Md invested in 0% or 1.10M shares. First Mercantile Com holds 0.02% or 9,260 shares in its portfolio.

Since September 18, 2017, it had 0 insider purchases, and 2 selling transactions for $56,020 activity.

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) reached all time high today, Feb, 15 and still has $26.99 target or 6.00 % above today’s $25.46 share price. This indicates more upside for the $874.24M company. This technical setup was reported by Barchart.com. If the $26.99 PT is reached, the company will be worth $52.45 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 3.33% or $0.82 during the last trading session, reaching $25.46. About 499,834 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 81.25% since February 15, 2017 and is uptrending. It has outperformed by 64.55% the S&P500.

Analysts await GlycoMimetics, Inc. (NASDAQ:GLYC) to report earnings on March, 7. They expect $-0.26 earnings per share, up 27.78 % or $0.10 from last year’s $-0.36 per share. After $-0.24 actual earnings per share reported by GlycoMimetics, Inc. for the previous quarter, Wall Street now forecasts 8.33 % negative EPS growth.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 5 analysts covering GlycoMimetics (NASDAQ:GLYC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GlycoMimetics had 16 analyst reports since August 10, 2015 according to SRatingsIntel. Stifel Nicolaus maintained GlycoMimetics, Inc. (NASDAQ:GLYC) on Thursday, August 3 with “Buy” rating. The stock has “Outperform” rating by Cowen & Co on Monday, August 15. The rating was maintained by SunTrust on Tuesday, October 3 with “Buy”. The firm has “Buy” rating by Jefferies given on Friday, July 7. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) earned “Buy” rating by Jefferies on Tuesday, December 12. The firm has “Hold” rating given on Monday, August 10 by Zacks. As per Thursday, February 8, the company rating was maintained by Roth Capital. Roth Capital maintained GlycoMimetics, Inc. (NASDAQ:GLYC) on Wednesday, November 1 with “Buy” rating. Jefferies maintained GlycoMimetics, Inc. (NASDAQ:GLYC) rating on Tuesday, September 12. Jefferies has “Buy” rating and $16.0 target. The rating was maintained by Jefferies with “Buy” on Monday, June 5.

Another recent and important GlycoMimetics, Inc. (NASDAQ:GLYC) news was published by Businesswire.com which published an article titled: “GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup …” on February 08, 2018.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $874.24 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.